

BARD1 APPOINTS DR GREGORY RICE AS CSO TO ACCELERATE DIAGNOSTIC TEST COMMERCIALISATION

- **BARD1 appoints eminent medical researcher Dr Greg Rice as Chief Scientific Officer (CSO) to accelerate the commercial development of its diagnostic tests**
- **Dr Rice has extensive commercial and academic experience and expertise in biomarker discovery, IP, diagnostics development, quality and regulatory compliance and a track record in developing and commercialising diagnostic tests**
- **Dr Peter French transitions to a consulting role as Strategic Technology Advisor continuing to support the Company's R&D programs**

Melbourne, Australia, 16 September 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) is pleased to announce the appointment of world-leading medical researcher Dr Gregory Rice PhD as Chief Scientific Officer (CSO), effective 20 September 2021.

Dr Rice will lead the Company's Research and Development (R&D) programs with responsibility for providing scientific leadership, planning R&D strategies, implementing best practice and advancing its diagnostic development programs to achieve value-generating clinical and commercial milestones.

Dr Greg Rice PhD, BSc (Hon), MHA, Grad Dip Mgt is an internationally recognised academic and commercial scientist with over 30 years' expertise and experience in oncology, perinatology, exosome-based research, clinical translational research, IVD development and commercialisation. He has held senior academic appointments, co-founded hospital-based clinical research centres in both oncology and perinatology, and co-founded and led diagnostic companies. He is an award-winning scientist with a strong international profile and clinical research networks. He has published more than 280 peer-reviewed scientific publications and is a regular invited speaker at international conferences. His academic qualifications include a Doctor of Philosophy and Bachelor of Science (First Class Honours) from the University of Western Australia and a Graduate Diploma in Management and Master of Health Administration from RMIT University.

Dr Rice has held numerous executive leadership positions throughout his academic career including at the University of Queensland (UQ), Baker Heart and Diabetes Institute, University of Melbourne and Monash University. Notably, as Director of the UQ Centre for Clinical Diagnostics (CCD), he established the Centre, implemented an ISO17025 quality management system, secured NATA accreditation, and established an exosome research facility to evaluate the clinical utility of extracellular vesicles as liquid biopsies, IVDs and therapeutics. Additionally, as Deputy Director and Acting Director of UQ Centre for Clinical Research (UQCCR) and as Deputy Associate Dean (Research), he provided strategic and operational leadership for over 200 research staff and students. He was also a Founding Director of the Women's Cancer Foundation and Ovarian Cancer Institute in Melbourne. Currently, he is an Honorary Professor in the Faculty of Medicine at the University of Queensland, and Visiting Professor in the Faculty of Medicine, University of the Andes, Santiago, Chile.

Dr Rice has significant research and commercialisation experience focused on the identification and validation of disease biomarkers, and development of In Vitro Diagnostic Multivariate Index Assays (IVDMIAs) for ovarian cancer and obstetrical syndromes, and their translation into clinical applications. During his career he has successfully delivered diagnostic products from concept-to-market. Dr Rice was a Founding Director and COO of diagnostics company HealthLinx Ltd focused on the development and commercialisation of cancer diagnostics, and more recently CEO of University of the Andes (Chile) spinout company Pregnostica SpA developing diagnostics for gestational diabetes. Dr Rice has also served as a member of Clinical and Scientific Advisory Committees of ASX-listed biotechnology companies and as a member of the Technical and Regulatory Standing Committee of IVD Australia.

CEO Dr Learne Hinch said; "We are extremely pleased to appoint someone of Greg's calibre and experience to lead the Company's R&D team and programs into the clinical development and commercialisation phase. Greg is a data-driven and commercially focused scientist with a track record in cancer diagnostics and is strongly motivated to deliver clinically important diagnostics to improve patient

outcomes and save lives. Whilst his focus will be on advancing the Company's lead SubB2M tests for breast and ovarian cancers towards clinical and commercial milestones, he will also build our next generation exosome-based diagnostic pipeline and support our BARD1 and hTERT programs. I greatly look forward to working with Greg to progress our diagnostic pipeline, achieve key milestones and ultimately deliver lifesaving diagnostic products to patients."

Dr Greg Rice said; "I am delighted to join the Company, which is well-positioned for this next growth phase, as it moves to commercialise its lead diagnostic tests for breast and ovarian cancers. My translational research interests and career focus have been on oncology, diagnostics, women's health, and exosome-based technologies, which are strongly aligned with BARD1's diagnostic portfolio and commitment to improving patient health outcomes. My goals are to: ensure the timely delivery of clinically relevant products; achievement of key clinical milestones; and regulatory approvals initially in the US and Europe. I greatly look forward to leading and motivating the R&D team to advance the diagnostic pipeline through clinical development to market."

Dr Peter French, the previous CSO, is committed to an ongoing consulting role with the Company as Strategic Technology Advisor, where he will provide ongoing strategic advice, scientific expertise and technical support. As CSO, Dr French provided strong scientific leadership to translate the Company's SubB2M and Molecular NET technologies into clinically actionable products with key achievements including POC for the SubB2M ELISA test for ovarian cancer, commercialisation of the EXO-NET® RUO exosome capture tool launched in May 2021, and establishment of multiple collaborations with academia and industry for development of SubB2M, EXO-NET and type 3c diabetes products. We thank Dr French for his scientific leadership and guidance over the past 12-months and look forward to his ongoing contributions.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
CEO
E leearne@bard1.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@bard1.com
M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is an Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. BARD1 has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers. For more information on BARD1, see www.bard1.com and www.exo-net.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.